NeuroRPM’s FDA-cleared wearable platform is being used to monitor digital biomarkers in the open-label ANVS-25002 trial in Parkinson’s disease. The study is expected to enroll approximately 500 participants at multiple clinical sites, and eligible participants may join NeuroRPM monitoring to supplement planned study assessments with continuous real-world symptom tracking.
The NeuroRPM platform uses the Apple Watch to collect and analyze movement data during daily activities to provide continuous measurement of motor symptoms including bradykinesia, tremor, and dyskinesia. Its platform is the first FDA-cleared medical device with AI for continuous monitoring of Parkinson’s symptoms, and advanced algorithms translate data from wearable sensors into digital biomarkers to help researchers assess treatment response with greater precision.
Annovis Bio is a Phase 3 clinical stage biotech company developing buntanetap, a once-daily oral treatment; the ANVS-25002 study is evaluating this candidate in people with Parkinson’s disease. After the study, participants may continue to use NeuroRPM for ongoing clinical monitoring by prescription.
Post NeuroRPM to provide AI monitoring for Annovis Parkinson’s trial appeared first Long time. Technology.
